NCT05117177 is a Phase 1 clinical trial of Inupadenant in Solid Tumor, Adult, sponsored by iTeos Therapeutics.

Who is sponsoring NCT05117177?

NCT05117177 is sponsored by iTeos Therapeutics.

What drugs are being tested in NCT05117177?

Interventions in NCT05117177: Inupadenant, Inupadenant, Inupadenant.

What condition does NCT05117177 study?

NCT05117177 studies Solid Tumor, Adult.

Is NCT05117177 still recruiting?

NCT05117177 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05117177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

Completed Phase 1 Last updated 19 September 2024

What this trial tests

Phase 1 trial testing Inupadenant in Solid Tumor, Adult in 57 participants. Completed in 9 May 2024.

Timeline

1 July 2021

Primary endpoint
9 May 2024

9 May 2024

Quick facts

Lead sponsor	iTeos Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	1 July 2021
Primary completion	9 May 2024
Estimated completion	9 May 2024
Sites	5 locations across Belgium, United Kingdom

Drugs / interventions tested

Inupadenant — full drug profile →
Inupadenant — full drug profile →
Inupadenant — full drug profile →

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

iTeos Therapeutics — full company profile →

Who can join

18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A2A-004 is a three-part multicenter, open-label, Phase I clinical trial intended to evaluate the safety and tolerability, and the pharmacokinetics (PK) and food effect of new formulations of inupadenant (formerly known as EOS100850), in participants with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C, Yin S, To KKW, Fu L. · · 2023 · cited 230× · PMID 36859386 · DOI 10.1186/s12943-023-01733-x
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, et al · · 2023 · cited 58× · PMID 37345056 · DOI 10.3390/cancers15102718
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X, Xie L. · · 2022 · cited 54× · PMID 35836249 · DOI 10.1186/s13046-022-02430-1
Small-molecule agents for cancer immunotherapy.
Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.
Wang L, Zhang J, Zhang W, Zheng M, et al · · 2024 · cited 28× · PMID 38799637 · DOI 10.1016/j.apsb.2023.12.004
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.
Zahavi D, Hodge JW. · · 2023 · cited 21× · PMID 37240219 · DOI 10.3390/ijms24108871
Pathophysiological Role and Medicinal Chemistry of A<sub>2A</sub> Adenosine Receptor Antagonists in Alzheimer's Disease.
Merighi S, Borea PA, Varani K, Vincenzi F, et al · · 2022 · cited 17× · PMID 35566035 · DOI 10.3390/molecules27092680
Adenosine signaling: Optimal target for gastric cancer immunotherapy.
Wang J, Du L, Chen X. · · 2022 · cited 14× · PMID 36189223 · DOI 10.3389/fimmu.2022.1027838

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other iTeos Therapeutics trials

Trials by the same sponsor.

NCT05289492 — Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated
NCT04335253 — First-In-Human Study of EOS884448 in Participants with Advanced Cancers. · Phase 1 · completed
NCT03873883 — First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05117177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by iTeos Therapeutics
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing